GENEVA, Aug. 7 -- KADMON CORPORATION, LLC filed a patent application (US2026/012660) for “COMBINATION THERAPY COMPRISING BELUMOSUDIL AND GUSACITINIB”. With publication no. WO/2026/165001, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 31/517
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....